Literature DB >> 31028457

Mutations in CDKN2A and the FGFR3 genes on bladder cancer diagnosis: a systematic review and meta-analysis.

Herney Andrés García-Perdomo1,2, Juan Pablo Usubillaga-Velasquez2, James Alejandro Zapata-Copete3, Leonardo Oliveira Reis4.   

Abstract

PURPOSE: To determine the association between mutations in CDKN2A and FGFR3 genes and the diagnosis of bladder carcinoma (BCa).
METHODS: A systematic search strategy was carried out through MEDLINE, EMBASE, LILACS, CENTRAL and unpublished literature. We included RCTs, cohort, case-control and cross-sectional studies that involved patients > 18-year-old assessing the association between CDKN2A and FGFR3 mutated genes and BCa. The primary outcome was bladder cancer defined by histology of the sample. We assessed the risk of bias with QUADAS2 and performed a meta-analysis with Review Manager v5.3.
RESULTS: We found 97 records with the search strategies. After duplicates were removed, six studies were included in meta-analysis. Regarding the association between mutated FGFR3 and bladder cancer, we found an OR 31 95% CI (15-64). However, there was no association for CDKN2A and BCa.
CONCLUSION: There is a strong association between FGFR3 mutated gene and the diagnosis of bladder cancer, which has not been observed with CDKN2A. Such a result supports FGFR3 mutated gene as a promissory bladder cancer screening and monitoring biomarker.

Entities:  

Keywords:  Bladder cancer; CDKN2A; Diagnosis; FGFR3; Genes

Mesh:

Substances:

Year:  2019        PMID: 31028457     DOI: 10.1007/s00345-019-02779-7

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  13 in total

1.  A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.

Authors:  Christina M Dahmcke; Kenneth E Steven; Louise K Larsen; Asger L Poulsen; Ahmad Abdul-Al; Christina Dahl; Per Guldberg
Journal:  Eur Urol       Date:  2016-07-11       Impact factor: 20.096

2.  Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.

Authors:  Kim E M van Kessel; Willemien Beukers; Irene Lurkin; Angelique Ziel-van der Made; Kirstin A van der Keur; Joost L Boormans; Lars Dyrskjøt; Mirari Márquez; Torben F Ørntoft; Francisco X Real; Ulrika Segersten; Núria Malats; Per-Uno Malmström; Wim Van Criekinge; Ellen C Zwarthoff
Journal:  J Urol       Date:  2016-10-13       Impact factor: 7.450

3.  Expression of p16 and cyclin D1 in bladder cancer and correlation in cancer progression.

Authors:  Ching-Chiang Yang; Kang-Chu Chu; Huey-Yi Chen; Wen-Chi Chen
Journal:  Urol Int       Date:  2002       Impact factor: 2.089

4.  Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.

Authors:  Mohammad Obaidul Hoque; Shahnaz Begum; Ozlem Topaloglu; Aditi Chatterjee; Eli Rosenbaum; Wim Van Criekinge; William H Westra; Mark Schoenberg; Marianna Zahurak; Steven N Goodman; David Sidransky
Journal:  J Natl Cancer Inst       Date:  2006-07-19       Impact factor: 13.506

5.  TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis.

Authors:  Nicolas Noel; Jerome Couteau; Geraldine Maillet; Françoise Gobet; Françoise D'Aloisio; Christophe Minier; Christian Pfister
Journal:  Anticancer Res       Date:  2015-09       Impact factor: 2.480

6.  Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Philippe E Spiess; Neeraj Agarwal; Rick Bangs; Stephen A Boorjian; Mark K Buyyounouski; Peter E Clark; Tracy M Downs; Jason A Efstathiou; Thomas W Flaig; Terence Friedlander; Richard E Greenberg; Khurshid A Guru; Noah Hahn; Harry W Herr; Christopher Hoimes; Brant A Inman; Masahito Jimbo; A Karim Kader; Subodh M Lele; Joshua J Meeks; Jeff Michalski; Jeffrey S Montgomery; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Mark A Preston; Wade J Sexton; Arlene O Siefker-Radtke; Guru Sonpavde; Jonathan Tward; Geoffrey Wile; Mary A Dwyer; Lisa A Gurski
Journal:  J Natl Compr Canc Netw       Date:  2017-10       Impact factor: 11.908

Review 7.  Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.

Authors:  Sam S Chang; Stephen A Boorjian; Roger Chou; Peter E Clark; Siamak Daneshmand; Badrinath R Konety; Raj Pruthi; Diane Z Quale; Chad R Ritch; John D Seigne; Eila Curlee Skinner; Norm D Smith; James M McKiernan
Journal:  J Urol       Date:  2016-06-16       Impact factor: 7.450

8.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21

10.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962

View more
  2 in total

1.  Non-muscle invasive bladder cancer (NMIBC): boiling arena and promissory future.

Authors:  Leonardo O Reis
Journal:  World J Urol       Date:  2019-10       Impact factor: 4.226

2.  The origin of bladder cancer from mucosal field effects.

Authors:  Jolanta Bondaruk; Roman Jaksik; Ziqiao Wang; David Cogdell; Sangkyou Lee; Yujie Chen; Khanh Ngoc Dinh; Tadeusz Majewski; Li Zhang; Shaolong Cao; Feng Tian; Hui Yao; Paweł Kuś; Huiqin Chen; John N Weinstein; Neema Navai; Colin Dinney; Jianjun Gao; Dan Theodorescu; Christopher Logothetis; Charles C Guo; Wenyi Wang; David McConkey; Peng Wei; Marek Kimmel; Bogdan Czerniak
Journal:  iScience       Date:  2022-06-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.